University of Birmingham Confidence in Concept

Lead Research Organisation: University of Birmingham

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
 
Description CRUK/16/030 AmpseqUr Amplicon deep sequencing of Urinary DNA for the detection of bladder cancer
Amount £282,155 (GBP)
Funding ID 23590 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 07/2020
 
Description Development and validation of a synthetic sugar recognition technology for prostate cancer risk stratification
Amount £274,945 (GBP)
Funding ID RIA17-ST2-020 
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2019 
End 03/2021
 
Description Identification Of New Adjunctive Treatments For Bladder Cancer
Amount £7,500 (GBP)
Organisation Action Bladder Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 03/2018
 
Description Innovate UK- Advanced Therapy Treatment Centres
Amount £7,300,000 (GBP)
Organisation University of Birmingham 
Sector Academic/University
Country United Kingdom
Start 01/2018 
 
Description Investigating GPCR:RAMP interactions using nanobodies
Amount £404,022 (GBP)
Funding ID BB/R016615/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 06/2021
 
Description MRC Confidence in Concept
Amount £97,433 (GBP)
Funding ID CiC 6.1 Lalor 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2019 
End 04/2021
 
Description MRC Stratified Medicine Initiative- Minimising mortality in alcoholic hepatitis
Amount £5,000,000 (GBP)
Organisation University of Birmingham 
Sector Academic/University
Country United Kingdom
Start 01/2017 
 
Description Wellcome ISSF
Amount £25,000 (GBP)
Funding ID WT ISSF 3 Lalor 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 04/2021
 
Description Wellcome ISSF
Amount £28,862 (GBP)
Funding ID ISSF3 959744 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 02/2021
 
Description working with Harwell Diamond light source 
Organisation MRC Harwell
Country United Kingdom 
Sector Academic/University 
PI Contribution £57,564 (in kind) of synchrotron beam time (beam line B23) at Diamond has been secured to address academic questions pertaining to the peptides structure and their interaction with collagen.
Collaborator Contribution allowing use of facility
Impact n/a
Start Year 2017
 
Title TREATMENT OF ACUTE LIVER FAILURE 
Description The present invention relates to the treatment or prophylaxis of acute liver failure. More particularly, the invention relates to use of an agent that modulates the podoplanin pathway, such as by inhibiting an interaction of podoplanin with CLEC-2 or inhibiting the activity of Src and/or Syk family kinases for the treatment or prophylaxis of acute liver failure, as well as a method for determining the efficacy of treatment of acute liver failure. 
IP Reference WO2018046877 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact n/a
 
Title TREATMENT OF CHRONIC INFLAMMATORY DISEASE 
Description The present invention relates to the treatment or prevention of a chronic inflammatory disease, condition or related pathology. More particularly, the invention relates to use of an agent that modulates the podoplanin pathway, such as by inhibiting an interaction of podoplanin with CLEC-2 or inhibits the activity of Src and/or Syk family kinases for use in a method of treating and/or preventing a chronic inflammatory disease, condition or related pathology in a subject. 
IP Reference WO2018046876 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact n/a